IART240517P22500
- 0.05
- 0.000.00%
Integra Lifesciences Newsroom
Citi Maintains Integra Lifesciences(IART.US) With Hold Rating, Cuts Target Price to $28
Citi analyst Joanne Wuensch maintains $Integra Lifesciences(IART.US)$ with a hold rating, and adjusts the target price from $38 to $28.According to TipRanks data, the analyst has a success rate of 62.
Integra Lifesciences(IART.US) Director Buys US$995.82K in Common Stock
$Integra Lifesciences(IART.US)$ Director HILL BARBARA B purchased 36,350 shares of common stock on May 21, 2024 at an average price of $27.3952 for a total value of $995.82K.Source: Announcement What
Integra Lifesciences Holdings Insider Bought Shares Worth $995,816, According to a Recent SEC Filing
Barbara B Hill, Director, on May 21, 2024, executed a purchase for 36,350 shares in Integra Lifesciences Holdings (IART) for $995,816. Following the Form 4 filing with the SEC, Hill has control over a
Integra LifeSciences Is Maintained at Neutral by Citigroup
Integra LifeSciences Is Maintained at Neutral by Citigroup
Express News | Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $28
Express News | Integra Lifesciences Holdings Corp : Citigroup Raises Target Price to $28 From $24
Sector Update: Health Care Stocks Steady Pre-Bell Friday
Health care stocks were steady pre-bell Friday as the Health Care Select Sector SPDR Fund (XLV) was recently inactive and the iShares Biotechnology ETF (IBB) was down a slight 0.1%. Doximity (DOCS) ra
Express News | Integra Lifesciences- Accelerated Share Repurchase Agreement With Morgan Stanley to Repurchase $50 Mln of Co’s Outstanding Shares of Common Stock
Express News | Integra Lifesciences Holdings- on May 16, Entered Accelerated Share Repurchase Agreement With Morgan Stanley & Co
Integra LifeSciences: Expansion, Audits, and Share Repurchase Plan
Express News | Integra Lifesciences Holdings: Planning $50 Mln Share Repurchase as a Part of Previous Approval by Board
Integra LifeSciences to Present at the 2024 Bank of America Healthcare Conference
PRINCETON, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will
Deciphering Integra (IART) International Revenue Trends
Have you evaluated the performance of Integra LifeSciences' (IART) international operations during the quarter that concluded in March 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
A Glimpse Into The Expert Outlook On Integra Lifesciences Through 8 Analysts
Analysts' ratings for Integra Lifesciences (NASDAQ:IART) over the last quarter vary from bullish to bearish, as provided by 8 analysts.The table below summarizes their recent ratings, showcasing the e
Integra LifeSciences Price Target Cut to $40.00/Share From $49.00 by JMP Securities
Integra LifeSciences Price Target Cut to $40.00/Share From $49.00 by JMP Securities
Integra's (IART) Q1 Earnings Match Estimates, Margins Down
Integra LifeSciences Holdings Corporation IART delivered adjusted earnings per share (EPS) of 55 cents in the first quarter of 2024, down 25.7% year over year.
Oppenheimer Cuts Integra to Perform, Cites Boston Plant Delays
Integra LifeSciences Cut to Equal-Weight From Overweight by Wells Fargo
Integra LifeSciences Cut to Equal-Weight From Overweight by Wells Fargo
Wells Fargo Downgrades Integra Lifesciences to Equal-Weight, Lowers Price Target to $25
Wells Fargo analyst Vik Chopra downgrades Integra Lifesciences (NASDAQ:IART) from Overweight to Equal-Weight and lowers the price target from $45 to $25.
Integra Lifesciences (IART) Was Downgraded to a Hold Rating at Oppenheimer